OB and Anesthesia: 165 years of Marital Bliss

March 15, 2023 at 8 pm ET

---

FREE for ObGFirst® Members and ObG Resident CORE™ Members!

Includes CME

---

Faculty: Joshua Younger, MD
Moderator: Tracy Shevell, MD

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high-quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Joshua Younger, MD has nothing to disclose
The PIM and ObGProject planners and others have nothing to disclose

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and The ObG Project. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education 

Postgraduate Institute for Medicine designates this live activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

The Sweet Spot: Managing Diabetes in Pregnancy in a Busy Practice

Recorded on February 15, 2023 at 8 pm ET

---

FREE for ObGFirst® Members and ObG Resident CORE™ Members!

Includes CME

---

Faculty: James Bedell, DO
Moderator: Tracy Shevell, MD

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high-quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

James Bedell, DO has nothing to disclose
The PIM and ObGProject planners and others have nothing to disclose

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and The ObG Project. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education 

Postgraduate Institute for Medicine designates this live activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Vulvar Disease: Diagnosis and Management

Recorded on January 18, 2023 at 8 pm ET

---

FREE for ObGFirst® Members and ObG Resident CORE™ Members!

Includes CME

---

Faculty: Karen Nishida, MD
Moderator: Brian Hines, MD

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high-quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Karen Nishida, MD has nothing to disclose
The PIM and ObGProject planners and others have nothing to disclose

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and The ObG Project. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education 

Postgraduate Institute for Medicine designates this live activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Intrauterine Resuscitation of Category II Fetal Tracings: Evidence and the Unknowns

Recorded on December 21, 2022 at 8 pm ET

---

FREE for ObGFirst® Members and ObG Resident CORE™ Members!

Includes CME

---

Faculty: Nandini Raghuraman MD MSCI
Moderator: Susan Gross MD FRCSC FACOG FACMG

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high-quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Nandini Raghuraman MD MSCI has nothing to disclose
The PIM and ObGProject planners and others have nothing to disclose

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and The ObG Project. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education 

Postgraduate Institute for Medicine designates this live activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Carrier Screening for SMA

Recorded on November 21st, 2022 at 8 pm ET

---

FREE for ObGFirst® Members and ObG Resident CORE™ Members!

Includes CME

---

Faculty: Esther Rose, MS CGC and Tamar Goldwaser, MD, FACOG, FACMG 
Moderator: Tracy Shevell, MD

Learning Objectives 

1. The learner will be able to recognize signs and symptoms of SMA
2. The learner will be able to interpret SMA carrier screening result
3. The learner will be able to identify reproductive options for SMA carrier couples

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high-quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Esther Rose, MS CGC and Tamar Goldwaser, MD, FACOG, FACMG have nothing to disclose
The PIM and ObGProject planners and others have nothing to disclose

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and The ObG Project. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education 

Postgraduate Institute for Medicine designates this live activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Atrial Fibrillation: Diagnosis and Management

SUMMARY:

Atrial fibrillation, the most common cardiac arrhythmia, increases stroke risk and can exacerbate underlying heart disease. The 2014 ACC/AHA/HRS Guideline for the Management of Patients with Atrial Fibrillation offers a comprehensive approach to treating this condition. A focused update released in 2019 includes new evidence in support of novel drugs and devices to prevent thromboembolism, as well as other clinical considerations. Of note, these recommendations apply to atrial fibrillation (AF) and atrial flutter, regardless of the pattern of arrhythmia (i.e. paroxysmal, persistent, or permanent).

• Diagnosis and Workup
• Treatment Highlights
• Risk stratification
• Anticoagulation
• Alternatives to Anticoagulation
• Rate Control
• Rhythm Control

Diagnosis and Workup

• Diagnosed by EKG or cardiac monitoring: Characteristic irregular rhythm without discrete p-waves
• Workup at time of diagnosis should include
  • TTE | Thyroid function tests | CBC | Renal function and electrolytes | LFTs | CXR (if suspicion for heart failure or pulmonary disease) | Sleep study (if suspicion for sleep apnea)
• Outpatient management appropriate for hemodynamically stable patients without evidence of severe volume overload or acute coronary syndrome

Note: Routine screening for AF in the general population is not currently recommended by the USPSTF | The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for AF (I statement)

Treatment Highlights

• Mainstays of treatment for most patients are anticoagulation (warfarin vs. NOAC) and rate control (typically beta blocker or nondihydropyridine calcium channel blocker)
• For some patients, attempted cardioversion to sinus rhythm may be preferred initially
• Invasive procedures to ablate AF or occlude the LAA are appropriate for select patients

KEY POINTS:

• Valvular vs. non-valvular AF
  • Valvular: AF associated with moderate to severe mitral stenosis or mechanical heart valve
  • Non-valvular: All other AF (much more common)

Risk stratification

• CHA₂DS₂-VASc:  Estimates annual stroke risk for non-valvular AF, based on various demographic and comorbid factors
  • Anticoagulation is recommended for score ≥2 in men, ≥3 in women
  • Anticoagulation “may be considered” for score 1 in men, 2 in women; aspirin is also an option
• Stroke risk can be weighed against bleeding risk using clinical calculators such as HAS-BLED
  • However per ACC/AHA “their clinical utility is insufficient for use as evidence”
  • Higher bleeding risk may warrant closer monitoring of anticoagulated patients, but should not necessarily preclude anticoagulation

Anticoagulation

Choosing an anticoagulant

• Goal is to prevent thromboembolic events
• Decision to start anticoagulation should always involve discussion of risks vs benefits

Medications

• Warfarin
  • Indicated for all valvular AF
  • Goal INR 2-3
• Novel oral anticoagulants (NOACs) recommended over warfarin for non-valvular AF in absence of contraindications
  • Dabigatran (Pradaxa) | Rivaroxaban (Xarelto) | Apixaban (Eliquis) | Edoxaban (Savaysa)
  • All either superior or non-inferior to warfarin | Do not require INR monitoring | Have lower risk of major bleeding
  • All have reduced dose options for CKD

• ESRD
  • Use warfarin or apixaban (limited data to support this)
• Bridging
  • For patients with mechanical heart valves undergoing surgery or other invasive procedure, bridge with unfractionated or low molecular weight heparin to provide uninterrupted anticoagulation
  • For all others, a brief interruption of therapy without bridging is considered safe

• Anticoagulation with antiplatelet therapy
  • Patients with AF and recent coronary stenting who are on triple therapy (oral anticoagulant + aspirin + P2Y₁₂ inhibitor) may be narrowed to double therapy (warfarin, dabigatran, or rivaroxaban + P2Y₁₂ inhibitor) to reduce bleeding risk

Dosing

• Apixaban (Eliquis)
  • Usual dose: 5 mg twice a day
  • Adjusted dose: 2.5 mg twice a day if ≥2 of the following
    • Age: ≥80 years
    • Body weight: ≤60 kg
    • Serum creatinine: ≥1.5 mg/dL

Note:  Caution with use of apixaban and the following 

• Other medications that can interfere with hemostasis: May increase risk of bleeding
  • Aspirin and antiplatelet agents | Other anticoagulants | Heparin | Thrombolytic agents | SSRIs | SNRIs | NSAIDs (chronic use) | Fibrinolytics
• Combined P-gp and strong CYP3A4 inhibitors
  • Ketoconazole | Itraconazole | Ritonavir
  • Reduce dose by 50% in usual dosing regimen and do not use with 2.5 mg reduced dose | Dose does not need to be altered with clarithromycin
• Combined P-gp and strong CYP3A4 inducers: Avoid concomitant use
  • Rifampin | Carbamazepine | Phenytoin | St. John’s wort

---

• Dabigatran (Pradaxa)
  • CrCl >30 mL/min: 150 mg orally, twice daily
  • CrCl 15 to 30 mL/min: 75 mg orally, twice daily

Note: Exercise caution with use of dabigatran and the following

• P-gp inducers rifampin: Avoid coadministration
• P-gp inhibitors in patients with CrCl 30-50 mL/min: Reduce dose or avoid
• P-gp inhibitors in patients with CrCl <30 mL/min: Not recommended

---

• Rivaroxaban (Xarelto)
  • 15 or 20 mg, once daily with food

Note: Exercise caution with use of rivaroxaban and the following

• Avoid combined P-gp and strong CYP3A inhibitors and inducers
• Anticoagulants: Avoid concomitant use
• Renal impairment: Avoid or adjust dose
• Hepatic impairment: Avoid use in Child-Pugh B and C hepatic impairment or with any degree of hepatic disease associated with coagulopathy

Alternatives to Anticoagulation

• Since thromboemboli tend to develop in the left atrial appendage (LAA), non-pharmacologic strategies for minimizing stroke risk involve occluding or removing the LAA
  • Percutaneous LAA occlusion (Watchman device): For patients with a contraindication to long-term anticoagulation (however, must be able to receive periprocedural anticoagulation)
  • Surgical LAA occlusion/excision: Only for patients already undergoing cardiac surgery for another indication

Rate Control

• Goal: To reduce symptoms, improve intra-cardiac hemodynamics and perfusion, and prevent tachycardia-induced cardiomyopathy
• Choosing a rate control strategy
  • Beta blockers (metoprolol, carvedilol, atenolol) or nondihydropyridine calcium channel blockers (diltiazem, verapamil) are first-line
  • Avoid CCBs in heart failure with reduced EF
  • Second-line options include digoxin (possibly associated with increased mortality) and amiodarone (not for long-term use due to toxicities)
• Strict (<80 bpm) vs. lenient (<110 bpm) rate control
  • Lenient approach acceptable as long as patient is asymptomatic and with preserved EF

Rhythm Control

• Not superior to rate control and associated with increase in hospitalizations
• May be indicated for new-onset AF, persistent symptoms, difficulty achieving rate control, young age, or tachycardia-induced cardiomyopathy
  • These approaches generally require expert consultation
• Electrical cardioversion
  • In non-emergent setting, requires anticoagulation three weeks pre- and four weeks post-procedure (if duration of AF >48 hours or unknown)
  • Often preceded by TEE to exclude LA thrombus
• Maintaining sinus rhythm
  • Typically achieved with antiarrhythmics (e.g. amiodarone, dofetilide, flecainide)
  • Caution: These drugs have significant side effects and toxicities
• Catheter ablation
  • For symptomatic paroxysmal AF not responding to antiarrhythmic therapy

Pregnancy for Women with Substance Use Disorders

Recorded on October 19th, 2022 at 8 pm ET

---

FREE for ObGFirst® Members and ObG Resident CORE™ Members!

Includes CME | Event will be recorded

---

Faculty: Marcela Smid, MD, MA, MS
Moderator: Tracy Shevell, MD

Learning Objectives 

1. Define the difference between substance use and substance use disorder diagnosis
2. Recognize the course of substance use among pregnant and postpartum individuals
3. Explain the role of overdose in maternal morbidity and mortality in the United States

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high-quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Marcela Smid, MD, MA, MS has nothing to disclose
The PIM and ObGProject planners and others have nothing to disclose

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and The ObG Project. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education 

Postgraduate Institute for Medicine designates this live activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Evaluation and Management of Overactive Bladder and Stress Urinary Incontinence 

Recorded on September 21st, 2022 at 8 pm ET

---

FREE for ObGFirst® Members and ObG Resident CORE™ Members!

Includes CME | Event will be recorded

---

Faculty: Brian Hines, MD
Moderator: Tracy Shevell, MD

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high-quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Brian Hines, MD has nothing to disclose
The PIM and ObGProject planners and others have nothing to disclose

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and The ObG Project. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education 

Postgraduate Institute for Medicine designates this live activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Managing Persistent Pelvic Pain: Less Stress, Better Care in Clinical Practice

Recorded on August 17, 2022 at 8 pm ET

---

FREE for ObGFirst® Members and ObG Resident CORE™ Members!

Includes CME | Event will be recorded

---

Faculty: Georgine Lamvu, MD, MPH 
Moderator: Lia Wrenn, MD

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high-quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Georgine Lamvu, MD MPH has nothing to disclose
The PIM and ObGProject planners and others have nothing to disclose

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and The ObG Project. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education 

Postgraduate Institute for Medicine designates this live activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Urine Good Hands: Evaluation and Management of Bladder Pain

Recorded on July 20, 2022 at 8 pm ET

---

FREE for ObGFirst® Members and ObG Resident CORE™ Members!

Includes CME

---

Faculty: Jocelyn Fitzgerald, MD FACOG
Moderator: Lia Wrenn, MD

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high-quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Jocelyn Fitzgerald, MD FACOG has nothing to disclose
The PIM and ObGProject planners and others have nothing to disclose

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and The ObG Project. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education 

Postgraduate Institute for Medicine designates this live activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Chronic HTN & Pregnancy

Recorded on June 22, 2022 at 8 pm ET

---

FREE for ObGFirst® Members and ObG Resident CORE™ Members!

Includes CME

---

Faculty: Kim Boggess, MD
Moderator: Ashley Comfort, MD, FACOG

Learning Objectives 

1. Recognize treatment thresholds for hypertension in pregnancy 
2. Discuss pregnancy outcomes following medical treatment of chronic hypertension 

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high-quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Jeffrey D. Sperling, MD, MS has nothing to disclose
The PIM and ObGProject planners and others have nothing to disclose

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and The ObG Project. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education 

Postgraduate Institute for Medicine designates this live activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.